Invesaro

Stocks AAQL Financial statements

Financial statements

Antiaging Quantum Living Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Antiaging Quantum Living Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2018FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue00.010.010.010.821.03
Cost of revenue0000.390.33
Gross profit00.010.010.010.430.7
Selling and marketing0.070.160.16
General and administrative000.060.060.080.050.050.351.061.38
Operating expenses0.060.060.080.050.050.421.221.54
Operating income-00-0.06-0.06-0.07-0.05-0.04-0.41-0.79-0.84
Interest income00.010
Other non-operating income-00.01000.070.01
Pre-tax income-0.07-0.04-0.04-0.41-0.72-0.82
Income tax0.010.02
Net income-00-0.07-0.06-0.07-0.04-0.04-0.41-0.72-0.84
EBITDA-0.04-0.04-0.41-0.65-0.7
EPS, basic0.000.00-0.00-0.00-0.00-0.01-0.02-0.03
EPS, diluted0.000.000.00-0.00-0.00-0.01-0.02-0.03
Shares, basic (weighted)9.9930303030303031.5
Shares, diluted (weighted)9.9930303030303031.5

Balance sheet

FY2018FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash and equivalents0000.060.020.0100.170.370.5
Short-term investments00.010.01
Receivables00.090.03
Inventory0.22
Other current assets0.030.170.17
Total current assets00.010.030.130.070.0100.220.811.21
Property, plant and equipment000.220.120.15
Lease right-of-use assets0.540.640.35
Intangible assets0.010.01
Other non-current assets0.03
Total assets00.030.030.130.070.0201.011.591.72
Accounts payable00.060.050.39
Accrued liabilities0
Deferred revenue00.01000.010.1
Total current liabilities000.010.070.060.090.870.681.67
Lease liabilities0.130.370.32
Total liabilities000.010.070.070.060.091.432.722.4
Paid-in capital00.010.080.160.160.160.160.240.241.53
Retained earnings-0-0-0.07-0.13-0.2-0.24-0.28-0.69-1.41-2.25
Other comprehensive income00.010.01
Shareholders' equity00.020.020.06-0.01-0.05-0.09-0.41-1.13-0.68
Total equity00.020.020.06-0.01-0.05-0.09-0.41-1.13-0.68
Total liabilities and equity00.030.030.130.070.0201.011.591.72
Shares outstanding9.999.999.993030303030

Cash flow statement

FY2018FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Net income000.04-0.06-0.07-0.04-0.04-0.41-0.72-0.84
Depreciation and amortization000.010.140.13
Change in receivables-0-0.080.06
Change in inventory-0.22
Change in payables0.0100.01-0
Cash from operations-0-0-0.04-0.07-0.06-0.04-0.04-0.65-0.9-0.17
Capital expenditures-0
Cash from investing0.04-0.040.020.05-0.22-0.06-0.16
Stock issued0.010.1
Cash from financing00-00.17-0.010.021.041.170.46
Exchange rate effect-0
Net change in cash-0-000.06-0.04-0-0.010.170.20.13
Free cash flow-0.04
Income taxes paid0.010.02

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.58 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Gross margin53.0%Gross profit / revenue.
Operating margin-69.3%Operating income / revenue.
EBITDA margin-61.8%EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin-68.7%Pre-tax income / revenue.
Net margin-69.4%Net income / revenue.
Operating cash flow margin-31.1%Cash from operations / revenue.
Return on assets (ROA)-31.4%Net income / average total assets.
D&A / revenue7.4%Depreciation and amortization / revenue.

Growth

MetricValueHow it is calculated
Revenue growth, 1y26.5%Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y323.7%Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y206.9%Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y63.8%Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y272.4%Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y197.8%Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y8.4%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y1,144.0%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y90.7%Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y5.0%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y1.6%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y1.0%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio0.83xCurrent assets / current liabilities.
Quick ratio0.49x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio0.22x(Cash + short-term investments) / current liabilities.
Liabilities / assets130.5%Total liabilities / total assets.
Working capital-$477.4KCurrent assets - current liabilities.
Goodwill and intangibles / assets0.4%(Goodwill + intangible assets) / total assets.
Tangible book value-$1.0MShareholders' equity - goodwill - intangible assets.

Efficiency

MetricValueHow it is calculated
Asset turnover0.45xRevenue / average total assets.
Fixed asset turnover10.6xRevenue / average property, plant and equipment.
Inventory turnover2.02xCost of revenue / average inventory.
Days inventory180 days365 x average inventory / cost of revenue.
Receivables turnover1.98xRevenue / average receivables.
Days sales outstanding185 days365 x average receivables / revenue.
Days payables212 days365 x average accounts payable / cost of revenue.
Cash conversion cycle153 daysDays inventory + days sales outstanding - days payables.

Per share

MetricValueHow it is calculated
EPS, diluted-$0.03Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share$0.04Revenue / diluted weighted shares.
Operating cash flow per share-$0.01Cash from operations / diluted weighted shares.
Book value per share-$0.03Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$0.03Tangible book value / shares outstanding.
Cash per share$0.02(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$19.9MShare price x shares outstanding.
Enterprise value$19.3MMarket cap + total debt - cash - short-term investments.
P/S13.5xMarket cap / revenue.
EV/Sales13.1xEnterprise value / revenue.
Earnings yield-5.1%Net income / market cap (the inverse of P/E).
What was Antiaging Quantum Living Inc.'s revenue in fiscal 2026?

Antiaging Quantum Living Inc. reported revenue of $1.0M for fiscal 2026, 26.5% higher than the year before.

Was Antiaging Quantum Living Inc. profitable in fiscal 2026?

No. It reported a net loss of $837.6K.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Antiaging Quantum Living Inc.